Details for New Drug Application (NDA): 214826
✉ Email this page to a colleague
The generic ingredient in LOREEV XR is lorazepam. There are eleven drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the lorazepam profile page.
Suppliers and Packaging for NDA: 214826
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LOREEV XR | lorazepam | CAPSULE, EXTENDED RELEASE;ORAL | 214826 | NDA | A-S Medication Solutions | 50090-7592 | 50090-7592-0 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (50090-7592-0) |
| LOREEV XR | lorazepam | CAPSULE, EXTENDED RELEASE;ORAL | 214826 | NDA | Almatica Pharma LLC | 52427-658 | 52427-658-30 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (52427-658-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 1MG | ||||
| Approval Date: | Aug 27, 2021 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Jan 8, 2034 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS | ||||||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 2MG | ||||
| Approval Date: | Aug 27, 2021 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Jan 8, 2034 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS | ||||||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 3MG | ||||
| Approval Date: | Aug 27, 2021 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Start Trial | Patent Expiration: | Jan 8, 2034 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS | ||||||||
Complete Access Available with Subscription
